The medical and telehealth industries are seeing rapid shifts, starting with a stumble for digital health platform Hims. The company recently missed its sales targets, a drop driven by stiffening competition in the expanding telehealth market. Meanwhile, traditional pharmaceutical companies are forging major new global partnerships. Bristol Myers Squibb has teamed up with Chinese drugmaker Hengrui Pharma to replenish its drug pipeline. However, this partnership comes with an important caveat, as the more than a dozen programs included in the deal are still in the very early stages of development.
On the clinical front, patients are seeing new treatment options advance. Rigel Pharma has secured a deal with Arvinas and Pfizer to commercialize a newly approved breast cancer drug called Veppanu. Across the regulatory desk, BridgeBio has officially asked the Food and Drug Administration to approve encaleret. This medication is designed to treat autosomal dominant hypocalcemia type 1, often called ADh2, which is a rare genetic disease.
Finally, in a significant step for neurological care, Roche has secured regulatory clearance in Europe for a new diagnostic tool. The company has successfully developed a blood test specifically designed to detect Alzheimer's disease in its early stages.
Behind the scenes of new drug pricing policies, the pharmaceutical industry has been spending record amounts to influence federal lawmakers. In 2025, the broader pharmaceutical and health products industry spent an unprecedented $457.3 million on lobbying. A significant chunk of this came from just 17 companies anchoring the TrumpRx prescription program. These specific companies poured more than $130 million into federal lobbying efforts, representing a massive 23 percent increase that easily outpaced the rest of the industry. This trend shows no signs of slowing down, with early 2026 reports already indicating a 5.7 percent year-over-year increase.
Meanwhile, pharmaceutical giant Eli Lilly has hit a regulatory roadblock in India. The company recently paused an obesity awareness campaign called "We Know Now" out of an abundance of caution. This decision came after the Drugs Controller General of India, the country's main regulatory authority for medicines, issued an advisory. The regulator cautioned that the campaign might violate strict national rules that prohibit the direct or indirect advertising of prescription medications, such as Eli Lilly's drug Mounjaro, to everyday consumers.
It is important to keep in mind that these updates are based on financial tracking and regulatory developments, not clinical science. The lobbying figures come from the campaign finance tracking group OpenSecrets, while the Eli Lilly developments are based on news reports from Reuters. This means these findings reflect market trends rather than peer-reviewed medical data.
Most of the fat in our bodies stores excess energy, but we also have a specialized type called brown fat. Brown fat acts like a biological furnace, burning calories to generate heat and keep us warm. For years, scientists have known about this heat-producing ability but struggled to understand all the exact mechanisms behind it. Now, researchers at McGill University have discovered a hidden molecular switch that activates a powerful calorie-burning system within this specialized tissue.
The breakthrough comes down to a molecule called glycerol. When our bodies are exposed to cold temperatures, we naturally begin to break down stored fat, which releases glycerol into the system. The researchers found that this molecule does something remarkable. It activates an enzyme, a specific type of protein that sparks chemical reactions, known as TNAP.
When TNAP is turned on, it triggers a completely different and previously unexplained metabolic pathway that produces heat. Beyond just burning calories, the scientists note that activating this pathway might offer secondary physical benefits, including the potential to strengthen bones. However, these are fundamental laboratory discoveries at the molecular level. There is no human clinical trial data yet to confirm if these effects will safely translate to people.
A major South American tribunal has backed the Colombian government in a high-profile dispute over a crucial HIV medicine. Two years ago, Colombia issued a compulsory license for an HIV drug marketed by ViiV Healthcare. A compulsory license is a legal tool that allows a government to permit the production or sale of a patented product without the consent of the patent owner, typically to address urgent public health needs.
The Court of Justice of the Andean Community, a tribunal that settles trade and intellectual property disputes for Bolivia, Colombia, Ecuador, and Peru, upheld the move. The court ruled that Colombia properly justified its decision to issue the license on the grounds of public interest. Additionally, the tribunal confirmed that the government met its legal obligations by setting a specific expiration date for the licensing period.
The U.S. Supreme Court has stepped in to temporarily protect how patients receive the abortion medication mifepristone. In a recent emergency order, the justices paused a lower court ruling that would have blocked patients from getting the drug by mail or through telehealth appointments. For now, the medication remains accessible under current rules.
The dispute centers on a 2021 policy from the Food and Drug Administration that made it easier to prescribe the pill without a physical doctor visit. A federal appeals court recently tried to overturn this FDA policy, declaring that patients must see a medical provider in person before receiving the medication. Drug manufacturers Danco and GenBioPro quickly pushed back. They warned that abruptly changing the rules would create immediate regulatory chaos and disrupt time-sensitive medical care.
However, this Supreme Court decision is not a final legal resolution. The justices only issued an emergency stay, which acts as a temporary pause button on the restrictions while the underlying legal battle continues to work its way through the judicial system.
Public health officials have identified a new outbreak of Ebola, a severe viral illness, in a remote region of the Congo. The Africa Centres for Disease Control and Prevention confirmed the emergence of the virus in the country's Ituri province.
So far, the outbreak has been largely concentrated in two specific areas known as the Mongwalu and Rwampara health zones. In these communities, health authorities have recorded 65 deaths and are currently tracking 246 suspected cases of the disease.
It is important to note that this is an early-stage and developing situation. Medical officials caution that the 246 reported infections are still classified as suspected cases rather than fully confirmed illnesses, meaning the exact scale of the outbreak is still coming into focus.
Brain cells, or neurons, communicate using electrical signals. For a long time, scientists focused on a specific part of the neuron called the axon initial segment. Think of this area as the starting line for a neuron's electrical impulse. Until now, researchers believed this starting line only received "GABAergic" signals, which are essentially molecular brakes that calm the cell down. However, a new study reveals that this area is actually capable of being directly excited.
The researchers discovered that this direct excitement happens through newly identified, highly specialized structures they call "axonic spines." Rather than just waiting for signals to build up from other parts of the cell, these unique spines act like an express lane. They bypass the usual routes to directly jump-start action potentials, the electrical sparks that allow brain cells to talk to one another. By boosting how neurons fire, these spines act as a fast track to route information through the nervous system.
While this is a fascinating breakthrough in basic biology, it is important to view it as early-stage research. The current study outlines fundamental discoveries about how these structures work, but it lacks data on quantitative effect sizes. Furthermore, it does not specify whether these observations were made in living organisms or in isolated cells in a laboratory dish.
A major new European cardiology report highlights that people who eat a large amount of ultra-processed foods face a significantly higher risk of severe health issues. These conditions include heart disease, irregular heart rhythms, high blood pressure, diabetes, obesity, and even cardiovascular death.
What makes these items so harmful? Industrially manufactured foods are typically loaded with added sugar, salt, unhealthy fats, and artificial additives. Researchers note that this combination can disrupt the body's metabolism, which is the process of converting food into energy. A diet high in these products also triggers inflammation, a biological immune response that can damage tissues over time, and strongly promotes overeating.
Strikingly, these negative physical effects occur even when the products are marketed to consumers as healthy choices. However, it is worth noting a limitation in this early research abstract: it does not provide exact sample sizes or specific mathematical data regarding exactly how much the health risks increase. While the link is clear, the quantified risk metrics are not yet detailed.
An unnamed quantum technology company is preparing to enter the stock market through an Initial Public Offering, or IPO. This financial process allows private companies to sell shares to the broader public to raise capital. While the specific details of the firm's scientific work remain under wraps, the company has an established history of working closely with the biopharmaceutical company Amgen.
This partnership goes well beyond a simple collaboration. Amgen has directly invested money into the quantum firm, signaling a strong belief in its potential. A technology leader at Amgen has even publicly praised the company's system, describing it as an extraordinary platform.
Because the current information comes from a brief corporate announcement, many key details are still missing. We do not yet know the actual name of the firm, its specific research metrics, its internal financial figures, or the exact timeline for when the public offering will take place.
A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by.
However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age.
While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.
Walking might feel automatic, but it requires a staggering amount of hidden coordination. Every joint in every leg must move in perfect harmony. For decades, scientists have debated how the nervous system manages this feat. Does the central nervous system act like a master conductor, or do the legs guide themselves based on the physical sensations of each step? To solve this puzzle, researchers studied the fruit fly, a tiny insect with a highly traceable nervous system. By using a clever new method to temporarily block the sensory feedback from the insect's legs, scientists were able to separate the nervous system's internal instructions from the outside world's physical feedback.
The team discovered a beautiful division of labor. It turns out that each individual leg is governed by its own independent neural network, known as a central pattern generator. Think of it as a built-in metronome that naturally beats out a basic walking rhythm. However, this internal rhythm alone is not enough for graceful movement. The fly relies heavily on real-time sensory feedback, like the physical sensation of stepping on a surface, combined with top-down commands from the brain to fine-tune the steps.
While internal nerve pathways keep the six legs coordinated with one another, sensory inputs and brain commands constantly tweak the rhythm to suit the environment. The researchers even identified specific neurons coming down from the brain that act like a gas pedal to speed up the walking pace. By mapping these discoveries onto the fly's neural wiring, the scientists identified the potential circuit designs that make coordinated, six-legged walking possible.
We often get stuck in a rut doing the exact same jog or weight routine every day. But new research suggests that shaking up your physical activity could be a key factor in living a longer life. A massive observational study tracked over 100,000 people for more than three decades, and the results point to a clear benefit of mixing things up. Engaging in different types of exercise significantly lowers the risk of death compared to sticking to repetitive daily routines.
Interestingly, the researchers found that more is not always better. The life-extending benefits of adding variety to your workouts do not scale up forever. Instead, they level off at a certain optimal point, creating a sweet spot of physical activity. Hitting this balanced level of varied movement seems to offer the maximum protection against early mortality.
However, it is important to keep a few limitations in mind. While the massive size of the study makes the general findings highly robust, the current data does not quantify exactly how much your risk of death drops. Furthermore, the researchers have not yet defined the precise parameters of that sweet spot, meaning we do not yet have a flawless mathematical formula for the perfect weekly workout mix.
